Trials / Unknown
UnknownNCT05966701
The MAD Study of SSGJ-613 in Healthy Subjects
A Randomized, Double-blind, Placebo-controlled, Multiple Dose Escalation Phase I Clinical Study of Humanized Monoclonal Antibody Injection (SSGJ-613) in Healthy Adult Chinese Subjects
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety and tolerability of SSGJ-613 after multiple subcutaneous injections in healthy subjects.
Detailed description
The purposes of this study are to evaluate the safety and tolerability, PK characteristics and immunogenicity of SSGJ-613 after multiple subcutaneous injections in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SSGJ-613 | SSGJ-613 subcutaneous injection. |
| DRUG | Placebo | Placebo subcutaneous injection. |
Timeline
- Start date
- 2023-08-10
- Primary completion
- 2024-03-10
- Completion
- 2024-03-10
- First posted
- 2023-08-01
- Last updated
- 2023-08-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05966701. Inclusion in this directory is not an endorsement.